Merit Medical's 9% Growth and 142 bps Margin Gain Pass the Smell Test-But Summer Seasonality Is Next

Why Q2 2026 looks like a genuine operating beat

Merit did the harder thing: it grew revenue and expanded margins in the same quarter. Revenue of $418.8 million rose 10% year over year, while non-GAAP operating margin increased to 22.6%, up 142 basis points. Management also raised its full-year outlook after reporting adjusted earnings of $1.19 a share versus $0.96 consensus. That combination points to real demand and execution, not just accounting leverage.

The market reacted accordingly. Shares gained 3.1% in regular trading and added another 4.38% after hours following the July 30 release. That kind of move suggests investors viewed the quarter as more than a one-off print.

The question now is durability. Bears can argue that organic constant-currency growth of 9%-the fastest pace in three years-may have pushed expectations too high. But the quarter was broadly constructive: U.S. and international sales both grew, profitability improved, and guidance moved higher. With summer seasonality next, the near-term test is whether this momentum holds up.

What looks healthier across Merit's business

OneMark expands the procedure base

If you want to gauge whether the business is getting busier in the real world, start with the procedure pool. Merit's OneMark system expanded the addressable procedure market from 400,000 to 1.3 million annually after integrating View Point Medical into its oncology platform. That widens the settings and procedures where Merit can compete, which makes the growth story less about selling the same basket and more about expanding where the company can show up clinically.

OEM recovery and category balance support the sales quality

The channel also looks less like a one-quarter spike and more like a refill. Management highlighted recovery in the OEM business, with the OEM business rose 15% after a weak first quarter. That fits a destocking-and-refill pattern rather than a purely promotional pop. Just as important, growth was not concentrated in one niche: Merit reported balanced performance across Foundational and Therapeutic categories, with foundational products up 6% and therapeutic products up 14%.

Margin expansion has a credible operating source

Merit said margin improvement was driven by pricing discipline, better product mix, manufacturing changes, and supply-chain improvements. The earnings call also cited strategic shifts to Tijuana, more automation, and optimized logistics. Those are the kinds of changes that can help the company retain more of each dollar of revenue if demand remains steady.

Portfolio cleanup is also worth watching. Merit is pursuing SKU rationalization as part of its broader 2027-2029 planning. That does not guarantee near-term upside, but it suggests management is trying to simplify the catalog rather than hide behind it.

Summer seasonality is the next durability test

The main caution is that OEM can be uneven, and customer stocking cycles can make a recovery look stronger than underlying end demand. Management has already indicated that Q3 seasonality will result in a sequential step-down in revenue because of typical summer moderation in procedure volumes and physician vacations. If the company still tracks toward its updated outlook after that step-down, investors will have a better read on whether Q2 was the start of something durable rather than a timing bounce.

Full-year guidance and cash generation are the numbers to watch

After a quarter in which Merit grew sales, improved margins, and beat estimates, the next benchmark is full-year adjusted EPS guidance of $4.25 to $4.35. A normal summer slowdown is expected, so the key issue is not whether growth stays hot, but whether the business remains close enough to the new guide to validate first-half momentum.

Merit has also generated $110.0 million of year-to-date operating cash flow and $76.6 million of year-to-date free cash flow. That matters because it shows the company is converting operations into cash even while dealing with trade headwinds and a seasonal dip.

For now, Merit looks like a proof-wait setup rather than a blind buy. If Q3 supports the raised outlook, the quarter should look more compelling in hindsight. If not, the market may treat this as a strong quarter inside a less durable recovery.